Genomic Risk Evaluation Using Oncotype DX in Young Women (Aged ≤40) With Early-stage, ER-positive, Human Epidermal Growth Factor Receptor 2-negative, and Node-negative Breast Cancer

Loading papers...

Genomic Risk Evaluation Using Oncotype DX in Young Women (Aged ≤40) With Early-stage, ER-positive, Human Epidermal Growth Factor Receptor 2-negative, and Node-negative Breast Cancer | InnScience